An exclusive licensing deal with The Rockefeller University will grant Bristol Myers Squibb exclusive rights for the development, manufacture and commercialization of its two-antibody COVID-19 therapy being tested in human trials. No financial terms of the agreement were disclosed.
BMS gains exclusive rights to COVID-19 antibody therapy
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.